Phytomedicine
Volume 16, Issue 5 , Pages 391-400 , May 2009

A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis

  • Samer S. El-Kamary

      Affiliations

    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, 660 West Redwood Street, Howard Hall, Rm 103C, Baltimore, MD 21201, USA
    • Corresponding Author InformationCorresponding author. Tel.: +14107062228; fax: +14107068013.
    • ,
  • Michelle D. Shardell

      Affiliations

    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, 660 West Redwood Street, Howard Hall, Rm 103C, Baltimore, MD 21201, USA
    • ,
  • Mohamed Abdel-Hamid

      Affiliations

    • National Hepatology and Tropical Medicine Research Institute, Kasr Al-Aini St, Cairo, Egypt
    • Minia University Faculty of Medicine, Minia, Egypt
    • ,
  • Soheir Ismail

      Affiliations

    • National Hepatology and Tropical Medicine Research Institute, Kasr Al-Aini St, Cairo, Egypt
    • ,
  • Mohamed El-Ateek

      Affiliations

    • Tanta Fever Hospital, Tanta, Gharbeya Governorate, Egypt
    • ,
  • Mohamed Metwally

      Affiliations

    • National Hepatology and Tropical Medicine Research Institute, Kasr Al-Aini St, Cairo, Egypt
    • Banha Fever Hospital and Banha University Faculty of Medicine, Banha, Kaloubeya Governorate, Egypt
    • ,
  • Nabiel Mikhail

      Affiliations

    • National Hepatology and Tropical Medicine Research Institute, Kasr Al-Aini St, Cairo, Egypt
    • Assiut University, South Egypt Cancer Institute, Assiut, Egypt
    • ,
  • Mohamed Hashem

      Affiliations

    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, 660 West Redwood Street, Howard Hall, Rm 103C, Baltimore, MD 21201, USA
    • National Hepatology and Tropical Medicine Research Institute, Kasr Al-Aini St, Cairo, Egypt
    • ,
  • Amr Mousa

      Affiliations

    • National Hepatology and Tropical Medicine Research Institute, Kasr Al-Aini St, Cairo, Egypt
    • ,
  • Amr Aboul-Fotouh

      Affiliations

    • Tropical Medicine Department, Cairo University Faculty of Medicine, Cairo, Egypt
    • ,
  • Mohamed El-Kassas

      Affiliations

    • National Hepatology and Tropical Medicine Research Institute, Kasr Al-Aini St, Cairo, Egypt
    • ,
  • Gamal Esmat

      Affiliations

    • National Hepatology and Tropical Medicine Research Institute, Kasr Al-Aini St, Cairo, Egypt
    • Tropical Medicine Department, Cairo University Faculty of Medicine, Cairo, Egypt
    • ,
  • G. Thomas Strickland

      Affiliations

    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, 660 West Redwood Street, Howard Hall, Rm 103C, Baltimore, MD 21201, USA

References 

  1. Abdel-Hamid M, Edelman DC, Highsmith WE, Constantine NT. Optimization, assessment, and proposed use of a direct nested reverse transcription-polymerase chain reaction protocol for the detection of hepatitis C virus. J. Hum. Virol. 1997;1:58–65
  2. Ball KR, Kowdley KV. A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. J. Clin. Gastroenterol. 2005;39:520–528
  3. Bode JC, Schmidt U, Durr HK. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial (author's transl.). Med. Klin. 1977;72:513–518
  4. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997;26:643–649
  5. Chalmers TC, Eckhardt RD, Reynolds WE, Cigarroa JG, Deane N, Reifenstein RW, et al. The treatment of acute infectious hepatitis. Controlled studies of the effects of diet, rest, and physical reconditioning on the acute course of the disease and on the incidence of relapses and residual abnormalities. J. Clin. Invest. 1955;34:1163–1235
  6. Corwin AL, Dai TC, Duc DD, Suu PI, Van NT, Ha LD, et al. Acute viral hepatitis in Hanoi, Viet Nam. Trans. R. Soc. Trop. Med. Hyg. 1996;90:647–648
  7. Deak G, Muzes G, Lang I, Niederland V, Nekam K, Gonzalez-Cabello R, et al. Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases. Orv. Hetil. 1990;131:1291–12921295–1296
  8. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135(5):1561–1567
  9. Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum. Toxicol. 1983;2:183–195
  10. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am. J. Med. 2002;113:506–515
  11. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J. Nat. Prod. 2003;66:1171–1174
  12. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern. Med. Rev. 1998;3:410–421
  13. Luper S. A review of plants used in the treatment of liver disease: part two. Altern. Med. Rev. 1999;4:178–188
  14. Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres (author's transl.). Med. Klin. 1978;73:1060–1065
  15. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J. Viral Hepat. 2005;12:559–567
  16. Meky FA, Stoszek SK, Abdel-Hamid M, Selim S, Abdel-Wahab A, Mikhail N, et al. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin. Infect. Dis. 2006;42:628–633
  17. Mulrow C, Lawrence V, Jacobs B, Dennehy C, Sapp J, Ramirez G, et al. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evid. Rep. Technol. Assess. (Summ.). 2000;1–3
  18. Muriel P, Mourelle M. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J. Appl. Toxicol. 1990;10:275–279
  19. Patera L. Silymarin in the treatment of acute viral hepatitis. Cesk. Gastroenterol. Vyz. 1978;32:533–534
  20. Pietrangelo A, Borella F, Casalgrandi G, Montosi G, Ceccarelli D, Gallesi D, et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology. 1995;109:1941–1949
  21. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am. J. Gastroenterol. 2005;100:2583–2591
  22. Robins J, Rotnitzky A, Zhao L. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. J. Am. Stat. Assoc. 1995;90:106–121
  23. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–2063
  24. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, et al. Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) Trial. Hepatology. 2008;47:605–612
  25. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005;5:558–567
  26. Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology. 2006;43:915–922
  27. Strickland GT, Tanamly MD, Tadros F, Labeeb S, Makld H, Nessim D, et al. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. Dig. Liver Dis. 2005;37:542–543
  28. Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig. Liver Dis. 2004;36:752–759
  29. Tsarev SA, Tsareva TS, Emerson SU, Kapikian AZ, Ticehurst J, London W, et al. ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates. J. Infect. Dis. 1993;168:369–378
  30. Vogel G, Tuchweber B, Trost W, Mengs U. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol. Appl. Pharmacol. 1984;73:355–362
  31. Wagner H, Diesel P, Seitz M. Arzneim. Forsch. 1974;24:466–471
  32. Wang Y, Ling R, Erker JC, Zhang H, Li H, Desai S, et al. A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis. J. Gen. Virol. 1999;80(Pt 1):169–177

PII: S0944-7113(09)00037-3

doi: 10.1016/j.phymed.2009.02.002

Phytomedicine
Volume 16, Issue 5 , Pages 391-400 , May 2009

Article Tools

* Image Usage & Resolution